Skip to main content
. 2023 Aug 23;14:1245228. doi: 10.3389/fneur.2023.1245228

Figure 2.

Figure 2

Changes between 2014 and 2020 in the number of botulinum toxin type A (BoNT-A) injections (A) in patients with central nervous system (CNS) lesions and in the number of patients (B) with CNS lesions treated with BoNT-A. MS, multiple sclerosis.